

Therapie der Plaque-Psoriasis, Teil 1

Lokaltherapie, UV-Therapie und konventionelle Systemtherapie

Traitement du psoriasis en plaques, partie 1

Traitement local, photothérapie et traitement systémique conventionnel

Literatur / Références

- 1 Christophers E. Psoriasis- epidemiology and clinical Spectrum. *Clin Exp Dermatol* 2001;26(4):314–20.
- 2 Melnikova. Psoriasis Market. *Nat Rev Drug Discov.* 2009;8(10):767–8.
- 3 Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res.* 2011;303(1):1–10.
- 4 Mehta N, Azfar R, Shin DB et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. *Heart J.* 2010;31(8):1000–6.
- 5 Boehnke WH. Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis: A Report from the GRAPPA 2010 Annual Meeting. *J Rheumatol.* 2012;39:441–4.
- 6 Gelfand JM, Neimann AL, Shin DB. Risk of myocardial infarction in patients with psoriasis. *JAMA.* 2006;11;296(14):1735–41.
- 7 Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. *J Eur Acad Dermatol Venereol.* 2011;25(9):1007–11.
- 8 Bremmer S, Van Voorhees AS, Hsu et al. National Psoriasis Foundation. Obesity and psoriasis:from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol.* 2010;63(6):1058–69.
- 9 Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. *J Am Acad Dermatol.* 2008;58(3):443–6.
- 10 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 44.
- 11 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 39.
- 12 Braun-Falco O. *Dermatologie und Venerologie.* 5. Auflage, Springer Verlag. S.485.
- 13 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 41.
- 14 Schmitt J, Meurer M. Topische Kombinationstherapien bei Psoriasis. *Hautarzt.* 2006;57(8):679–84.
- 15 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 58.
- 16 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 65.
- 17 *Arzneimittelkompendium der Schweiz,* 2012.
- 18 Mason AR, Mason J, Cork M et al. Topical treatments for chronic plaque psoriasis. *Cochrane Database Syst Rev.* 2009;15;(2):CD005028.
- 19 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 29.
- 20 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 37.
- 21 van Lümig PP, Driessen RJ, Berends MA Safety of treatment with biologics for psoriasis in daily practice: 5–year data. *J Eur Acad Dermatol Venereol.* 2012;26(3):283–91.
- 22 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 75.
- 23 Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol.* 2009;56.
- 24 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 67.
- 25 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 70.
- 26 Empfehlungen schweizerische Gesellschaft für Rheumatologie. <http://www.rheuma-net.ch/Richtlinien>.
- 27 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 117.
- 28 Papp K, Cather JC , Rosopht L al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. *Lancet.* 2012;380(9843):738–46.
- 29 Laws PM, Young HS. Current and emerging systemic treatment strategies for psoriasis. *Drugs.* 2012;72(14):1867–80.
- 30 Gupta AK, Goldfarb MT, Ellis CN et al.. Side-effect profile of acitretin therapy in psoriasis. *J Am Acad Dermatol.* 1989;20:1088–93.
- 31 van de Kerkhof PC, Cambazard F,Hutchinson PE et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. *Br J Dermatol.* 1998;138:84–9.

- 32 Saurat JH, Geiger JM, Amblard P et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. *Dermatologica*. 1988;177:218–24.
- 33 Gisondi P, Del Giglio M, Cotena C, Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. *Br J Dermatol*. 2008;158(6):1345–9.
- 34 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 135.
- 35 Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. *N Engl J Med*. 2003;349:658–65.
- 36 Nyfors A. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. *Dan Med Bull*. 1978;25:208–11.
- 37 Laburte C, Grossman R, Abi-Rached J et al. Efficacy and safety of oral cyclosporin A for long-term treatment of chronic severe plaque psoriasis. *Br J Dermatol*. 1994;130:366–75.
- 38 Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. *Br J Dermatol*. 1998;139:88–95.
- 39 Nast A, Boehncke WH, Mrowietz U et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2011, Seite 86.